Brian T. Hill
YOU?
Author Swipe
View article: Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma Open
The benefit of rituximab maintenance after first-line (1L) bendamustine and rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective s…
View article: Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study
Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study Open
Introduction: The CAR T cell therapy liso-cel showed promising efficacy and safety in patients with 3L+ R/R MZL in TRANSCEND FL (NCT04245839), a global, phase 2, open-label, single-arm, multicohort, pivotal study (Palomba ML, et al. Hemato…
View article: Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy
Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy Open
Introduction: Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL in the US and after ≥2 prior lines of therapy (LoT) including a BTKi in the EU. In the pivotal ZUMA-2 Cohort 1 study, brexu-cel induced …
View article: Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.
Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis. Open
Introduction: CD20xCD3 bispecific antibodies (BsAb) have been approved for use in relapsed/refractory (RR) large B-Cell lymphomas (LBCLs) with manageable toxicities. The main adverse events of clinical interest are cytokine release syndrom…
View article: Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions
Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions Open
Background Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective for patients with relapsed/refractory (R/R) follicular lymphoma (FL), but differ in treatment schedules and associated “time to…
View article: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R Open
Introduction: Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard of care therapy with frontline DA-EPOCH-R. However, treatment strategies following relapse after DA-EPOCH-R are not well…
View article: Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201 Open
To improve outcomes in relapsed or refractory activated B-cell type Diffuse Large B-cell Lymphoma (ABC-DLBCL), we launched a randomized phase 3 trial evaluating 2-year progression free survival (2yPFS) with the addition of ibrutinib to aut…
View article: Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry Open
Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2 lines of therapy. When used in…
View article: Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel Open
Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Emerging evide…
View article: Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma
Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma Open
Background: Loncastuximab tesirine (lonca) is active in patients with refractory or relapsed (r/r) aggressive B cell non-Hodgkin lymphoma (B-NHL) and is approved after 2 or more lines of therapy. The combination of lonca with venetoclax (V…
View article: <i>TP53</i>-Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers
<i>TP53</i>-Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers Open
Introduction: The effect of TP53 alterations on response to therapy is poorly understood in LBCL, with previous studies demonstrating worse overall survival (OS) for LBCL patients (pts) with TP53 aberrations. However, these studies pre-dat…
View article: Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission Open
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficac…
View article: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024 Open
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications h…
View article: BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation
BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation Open
[Image: see text]